Lymph node ratio-based prognostic model for risk stratification and individualized adjuvant therapy for postoperative major salivary duct carcinoma

Head Neck. 2023 Jul;45(7):1704-1716. doi: 10.1002/hed.27382. Epub 2023 Apr 28.

Abstract

Background: To investigate the value of lymph node ratio (LNR) for postoperative major salivary duct carcinoma (MSDC) and to establish a model for prognosis assessment and treatment optimization.

Methods: Data of MSDC were retrieved in public database, and prognostic factors were identified by univariate and multivariate analyses. A nomogram and risk stratification system were constructed.

Results: Four hundred and eleven eligible patients were included (training cohort vs. validation cohort: 287: 124). LNR ≥0.09 was associated with worse overall survival (OS). Age at diagnosis, sex, T stage, and LNR were identified as prognostic factors and integrated into nomogram. Low-risk patients were found to have better OS than high-risk patients. Furthermore, postoperative radiotherapy (PORT) significantly improved OS in the high-risk subgroup, but chemotherapy did not confer a long-term survival benefit.

Conclusions: A nomogram model integrating LNR could better assess postoperative prognosis and risk stratification in MSDC, and identify patients who might benefit from PORT to avoid overtreatment.

Keywords: adjuvant therapy; lymph node ratio; major salivary duct carcinoma; nomogram; prognosis.

MeSH terms

  • Carcinoma* / pathology
  • Humans
  • Lymph Node Excision
  • Lymph Node Ratio
  • Lymph Nodes* / pathology
  • Neoplasm Staging
  • Prognosis
  • Retrospective Studies
  • Risk Assessment
  • Salivary Ducts / pathology
  • Salivary Ducts / surgery

Substances

  • 10-methyl spiro(4.5)dec-6-en-6-carboxylic acid